JP2015224229A - 筋肉低下抑制組成物 - Google Patents
筋肉低下抑制組成物 Download PDFInfo
- Publication number
- JP2015224229A JP2015224229A JP2014110535A JP2014110535A JP2015224229A JP 2015224229 A JP2015224229 A JP 2015224229A JP 2014110535 A JP2014110535 A JP 2014110535A JP 2014110535 A JP2014110535 A JP 2014110535A JP 2015224229 A JP2015224229 A JP 2015224229A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- value
- decrease
- weeks
- muscle mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 128
- 210000003205 muscle Anatomy 0.000 title claims abstract description 35
- 230000002401 inhibitory effect Effects 0.000 title abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 45
- 241000237502 Ostreidae Species 0.000 claims abstract description 27
- 235000020636 oyster Nutrition 0.000 claims abstract description 27
- 208000001076 sarcopenia Diseases 0.000 claims abstract description 16
- 230000007423 decrease Effects 0.000 claims description 60
- 230000001629 suppression Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 20
- 206010028980 Neoplasm Diseases 0.000 abstract description 19
- 206010006895 Cachexia Diseases 0.000 abstract description 16
- 230000032683 aging Effects 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 2
- 241001482311 Trionychidae Species 0.000 abstract 4
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 42
- 238000012360 testing method Methods 0.000 description 40
- 230000008859 change Effects 0.000 description 24
- 239000003963 antioxidant agent Substances 0.000 description 20
- 230000003078 antioxidant effect Effects 0.000 description 20
- 230000037406 food intake Effects 0.000 description 16
- 235000013601 eggs Nutrition 0.000 description 15
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 12
- 235000019789 appetite Nutrition 0.000 description 10
- 230000036528 appetite Effects 0.000 description 10
- 108010088751 Albumins Proteins 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 108010074051 C-Reactive Protein Proteins 0.000 description 8
- 102100032752 C-reactive protein Human genes 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 6
- 229960003080 taurine Drugs 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- -1 iron ion Chemical class 0.000 description 5
- 241000270666 Testudines Species 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 208000002720 Malnutrition Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- QNGVNLMMEQUVQK-UHFFFAOYSA-N 4-n,4-n-diethylbenzene-1,4-diamine Chemical compound CCN(CC)C1=CC=C(N)C=C1 QNGVNLMMEQUVQK-UHFFFAOYSA-N 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
図2は、組成物が摂取者の食欲に与える影響を調べたものである。
0:食事量の0/5を摂取、1:食事量の1/5を摂取、2:食事量の2/5を摂取、
3:食事量の3/5を摂取、4:食事量の4/5を摂取、5:食事量の5/5を摂取
変化率は、(後値−0週間目の値)/0週間目の値×100(%)で算出した。
0:全く元気がない、1:ほとんど元気がない、2:あまり元気がない、
3:まあ元気がある、4:かなり元気がある、5:多いに元気がある
変化率は、(後値−0週間目の値)/0週間目の値×100(%)で算出した。
図4は、組成物が摂取者の体重に与える影響を調べたものである。
図6は、組成物が摂取者の筋量に与える影響を調べたものである。
BAPとは生体の抗酸化能力を測定するテスト法である。d−ROMsテストとは酸化ストレスを測定するテストである。修正BAP/d−ROMsとは潜在的抗酸化力を測定する指標である(永田勝太郎、長谷川拓也、広門靖正、喜山克彦、大槻千佳:生活習慣病と酸化ストレス防御系, 心身医学48(3):177-183, 2008.)。
修正BAP/d−ROMs値=BAP値/ d-ROMs値/ 7.510
これらの試験は、摂取者の血液を採取し、臨床検査室にて一般的な臨床検査機器にて
測定した。
図18は、組成物が摂取者の死亡率に与える影響を調べたものである。
Claims (3)
- すっぽんの粉末に、すっぽん卵とすっぽんの脂肪部から抽出したすっぽんオイルとを含有させたことを特徴とする筋量低下抑制組成物。
- カキ粉末を含有させることを特徴とする請求項1に記載の筋量低下抑制組成物。
- サルコペニアの状態にある人に与えるための請求項1または2のいずれかに記載の筋量低下抑制組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014110535A JP6021119B2 (ja) | 2014-05-28 | 2014-05-28 | 筋量低下抑制組成物 |
CN201510275860.0A CN105125583A (zh) | 2014-05-28 | 2015-05-27 | 抑制肌肉量降低的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014110535A JP6021119B2 (ja) | 2014-05-28 | 2014-05-28 | 筋量低下抑制組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015224229A true JP2015224229A (ja) | 2015-12-14 |
JP6021119B2 JP6021119B2 (ja) | 2016-11-02 |
Family
ID=54711405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014110535A Active JP6021119B2 (ja) | 2014-05-28 | 2014-05-28 | 筋量低下抑制組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6021119B2 (ja) |
CN (1) | CN105125583A (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105997823A (zh) * | 2016-07-14 | 2016-10-12 | 湖南湘湖水产有限公司 | 鳖油卵清美容面膜 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005143380A (ja) * | 2003-11-14 | 2005-06-09 | Domo Corporation:Kk | スッポン卵を使用した栄養食品 |
JP2013051937A (ja) * | 2011-09-06 | 2013-03-21 | Watanabe Oisutaa Kenkyusho:Kk | Orac値の高い抗酸化物質を多含有したカキ肉エキスの製造方法 |
JP2014047213A (ja) * | 2012-08-29 | 2014-03-17 | Marine Bioprocess Co Ltd | カキと海藻類の混合物の発酵物を有効成分で含むストレス解消または睡眠障害改善用組成物及びその製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1328984C (zh) * | 2004-12-22 | 2007-08-01 | 钟祥凤 | 甲鱼精制造法 |
CN1973687A (zh) * | 2005-11-28 | 2007-06-06 | 上海水产大学 | 一种保健蚝鳖粉 |
CN100574786C (zh) * | 2006-10-25 | 2009-12-30 | 黄学敏 | 一种甲鱼制剂的生产工艺 |
-
2014
- 2014-05-28 JP JP2014110535A patent/JP6021119B2/ja active Active
-
2015
- 2015-05-27 CN CN201510275860.0A patent/CN105125583A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005143380A (ja) * | 2003-11-14 | 2005-06-09 | Domo Corporation:Kk | スッポン卵を使用した栄養食品 |
JP2013051937A (ja) * | 2011-09-06 | 2013-03-21 | Watanabe Oisutaa Kenkyusho:Kk | Orac値の高い抗酸化物質を多含有したカキ肉エキスの製造方法 |
JP2014047213A (ja) * | 2012-08-29 | 2014-03-17 | Marine Bioprocess Co Ltd | カキと海藻類の混合物の発酵物を有効成分で含むストレス解消または睡眠障害改善用組成物及びその製造方法 |
Non-Patent Citations (6)
Title |
---|
JPN6016015003; 養殖 第35巻 第9号, p.30-34 * |
JPN6016015004; 食品と科学 第29巻 第11号, p.59-62 * |
JPN6016015006; レジデントノート Vol.13, No.12, 2011, p.2248-2252 * |
JPN6016015008; 栄養-評価と治療 Vol.30, No.3, 2013, p.199-201 * |
JPN6016015010; Modern Physician Vol.31, No.11, 2011, p.1362-1366 * |
JPN6016015011; 食品と開発 Vol.31, No.8, 1996, p.47-49 * |
Also Published As
Publication number | Publication date |
---|---|
JP6021119B2 (ja) | 2016-11-02 |
CN105125583A (zh) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | Beneficial effects of Korean red ginseng on lymphocyte DNA damage, antioxidant enzyme activity, and LDL oxidation in healthy participants: a randomized, double-blind, placebo-controlled trial | |
Cernat et al. | Serum trace metal and ceruloplasmin variability in individuals treated for pulmonary tuberculosis | |
Liu et al. | Black garlic improves heart function in patients with coronary heart disease by improving circulating antioxidant levels | |
Lal et al. | Comparative analysis of serum zinc, copper, magnesium, calcium and iron level in acute and chronic patients of visceral leishmaniasis | |
ES2586244T3 (es) | Utilización de cortezas de levadura para el tratamiento y/o la prevención de la hiperinsulinemia | |
Boşnak et al. | Oxidative stress in marasmic children: Relationships with leptin. | |
Mirhashemi et al. | Metabolic response to omega-3 fatty acids and vitamin e co-supplementation in patients with fibrocystic breast disease: a randomized, double-blind, placebo-controlled trial | |
Hininger-Favier et al. | Age-and sex-dependent effects of long-term zinc supplementation on essential trace element status and lipid metabolism in European subjects: the Zenith Study | |
JP6021119B2 (ja) | 筋量低下抑制組成物 | |
Oliveira et al. | Nutritional status and systemic inflammatory activity of colorectal patients on symbiotic supplementation | |
Grases et al. | Urinary phytate (Myo-inositol hexaphosphate) in healthy school children and risk of nephrolithiasis | |
Lin et al. | Nitric oxide production is paradoxically decreased after weight reduction surgery in morbid obesity patients | |
Apprey et al. | The assessment and prediction of malnutrition in children suffering from cancer in Ghana | |
El-Byoumy | Interleukin 6 as inflammatory marker and insulin resistance in obese Kuwaiti adolescents | |
Rauf et al. | Serum selenium concentration in liver cirrhotic patients suffering from hepatitis B and C in Pakistan | |
Watson | Oxidative stress and a high fat diet in rats: an intervention study on the effects of an organometallic compound on enzyme function, inflammatory markers, endotoxins and fasting serum glucose and insulin levels | |
Bunpo et al. | Effects of ascorbic acid supplementation on immune status in healthy women following a single bout of exercise | |
TWI811857B (zh) | 一種液化澱粉芽孢桿菌組合物用於預防或改善高血脂及相關疾病之用途 | |
Ahmed | A comparative estimation of metabolic and hormonal parameters among Iraqi hypothyroid patients | |
Wijayanti et al. | Consumption of Jelly Combination of Salacca Seed (Salacca zalacca) and Moringa Leaves Flour (Moringa oleifera) on Hemoglobin level in Female Adolescents with Moderate Anemia | |
Pusica et al. | The redox state of young female handball players following acute exercise and a one-month precompetitive training period | |
Malakul et al. | Effect of Naringin on Insulin Resistance and Oxidative Stress in Fructose Fed Rats | |
Pushparani | Serum zinc and iron level in type 2 diabetes mellitus with periodontitis | |
Helal et al. | Amelioration Effects of Aphanizomenon Flos-aqua (AFA) on Hazardous Effects of Mixture (Sodium Benzoate, Mono Sodium glutamate and Chlorophyllin) Intake in Male Albino Rats | |
Warz | Stable isotope ratios of carbon and nitrogen after weight loss A secondary analysis of the CarbFunc study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160624 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160913 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160927 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6021119 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |